Use of Strontium Chloride for the Treatment of Osteoporosis: A Case Report

被引:4
作者
Westberg, Sarah M. [1 ]
Awker, Amy [2 ]
Torkelson, Carolyn J. [3 ]
机构
[1] Univ Minnesota Twin Cities, Coll Pharm, Dept Pharmaceut Care & Hlth Syst, Minneapolis, MN 55455 USA
[2] Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA
[3] Univ Minnesota Twin Cities, Sch Med, Dept Family Med & Community Hlth, Minneapolis, MN USA
关键词
BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; RANELATE; RISK;
D O I
暂无
中图分类号
R [医药、卫生];
学科分类号
100218 [急诊医学];
摘要
Context center dot Strontium ranelate is an approved prescription medication for the treatment of osteoporosis in Europe. In the United States, the only available forms of strontium arc those that arc nonprescription, dietary supplements. Some patients with osteoporosis use those products because they prefer an alternate treatment to conventional therapy. Currently, no controlled trials have been conducted on the effectiveness of the supplements for treating osteoporosis. Objective center dot The study intended to examine how one woman responded to the use of strontium chloride. Design. this was a retrospective case study. Setting center dot The woman in the case study was a patient in an academic urban women's health clinic in Minneapolis, MN, USA. Participant center dot The participant was a postmenopausal woman with a history of vertebral fracture. Intervention center dot The participant took 680 mg daily of strontium chloride for 2.5 y. Outcome Measures center dot The patient had begun receiving dual-energy X-ray absorptiometry (DXA) scans in 2004 and continued to receive follow-up scans every 2 y After beginning strontium therapy in December 2011, she received DXA scans in March 2012 and May 2014. Results center dot During the study, the analysis of the patient's DXA scans showed a positive increase in the bone mineral density (BMD) of her vertebrae and her right hip and maintenance of her BMD in her left hip. Conclusions center dot Although the current case report does not provide enough evidence to conclude that US dietary supplements of strontium are effective in preventing fractures, it demonstrates a positive experience for one patient. (Ahern lher Health Med. 2016;22(3):66-70.)
引用
收藏
页码:66 / 70
页数:5
相关论文
共 19 条
[1]
[Anonymous], 2014, EUR PUBL ASS REP SUM
[2]
[Anonymous], 2014, CLIN GUID PREV TREAT
[3]
Dual effect of strontium ranelate:: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro [J].
Bonnelye, Edith ;
Chabadel, Anne ;
Saltel, Frederic ;
Jurdic, Pierre .
BONE, 2008, 42 (01) :129-138
[4]
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate [J].
Bruyere, Olivier ;
Roux, Christian ;
Detilleux, Johann ;
Slosman, Daniel O. ;
Spector, Tim D. ;
Fardellone, Patrice ;
Brixen, Kim ;
Devogelaer, Jean-Pierre ;
Diaz-Curiel, Manuel ;
Albanese, Carlina ;
Kaufman, Jean-Marc ;
Pors-Nielsen, Stig ;
Reginster, Jean-Yves .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08) :3076-3081
[5]
Effects of strontium ions on growth and dissolution of hydroxyapatite and on bone mineral detection [J].
Christoffersen, J ;
Christoffersen, MR ;
Kolthoff, N ;
Barenholdt, O .
BONE, 1997, 20 (01) :47-54
[6]
Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures An Updated Systematic Review [J].
Crandall, Carolyn J. ;
Newberry, Sydne J. ;
Diamant, Allison ;
Lim, Yee-Wei ;
Gellad, Walid F. ;
Booth, Marika J. ;
Motala, Aneesa ;
Shekelle, Paul G. .
ANNALS OF INTERNAL MEDICINE, 2014, 161 (10) :711-U163
[7]
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].
Cummings, SR ;
Black, DM ;
Thompson, DE ;
Applegate, WB ;
Barrett-Connor, E ;
Musliner, TA ;
Palermo, L ;
Prineas, R ;
Rubin, SM ;
Scott, JC ;
Vogt, T ;
Wallace, R ;
Yates, AJ ;
LaCroix, AZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082
[9]
European guidance for the diagnosis and management of osteoporosis in postmenopausal women [J].
Kanis, J. A. ;
McCloskey, E. V. ;
Johansson, H. ;
Cooper, C. ;
Rizzoli, R. ;
Reginster, J. -Y. .
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) :23-57
[10]
Interpretation and use of FRAX in clinical practice [J].
Kanis, J. A. ;
Hans, D. ;
Cooper, C. ;
Baim, S. ;
Bilezikian, J. P. ;
Binkley, N. ;
Cauley, J. A. ;
Compston, J. E. ;
Dawson-Hughes, B. ;
El-Hajj Fuleihan, Ghada ;
Johansson, H. ;
Leslie, W. D. ;
Lewiecki, E. M. ;
Luckey, M. ;
Oden, A. ;
Papapoulos, S. E. ;
Poiana, C. ;
Rizzoli, R. ;
Wahl, D. A. ;
McCloskey, E. V. .
OSTEOPOROSIS INTERNATIONAL, 2011, 22 (09) :2395-2411